Cargando…

Release of frustration drives corneal amyloid disaggregation by brain chaperone

TGFBI-related corneal dystrophy (CD) is characterized by the accumulation of insoluble protein deposits in the corneal tissues, eventually leading to progressive corneal opacity. Here we show that ATP-independent amyloid-β chaperone L-PGDS can effectively disaggregate corneal amyloids in surgically...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Yi Kimberly, Shi, Xiangyan, Anandalakshmi, Venkatraman, Neo, Dawn, Peh, Gary Swee Lim, Koh, Siew Kwan, Zhou, Lei, Abdul Rahim, M. K., Boo, Ketti, Lee, JiaXuan, Mohanram, Harini, Alag, Reema, Mu, Yuguang, Mehta, Jodhbir S., Pervushin, Konstantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063603/
https://www.ncbi.nlm.nih.gov/pubmed/36997596
http://dx.doi.org/10.1038/s42003-023-04725-1
Descripción
Sumario:TGFBI-related corneal dystrophy (CD) is characterized by the accumulation of insoluble protein deposits in the corneal tissues, eventually leading to progressive corneal opacity. Here we show that ATP-independent amyloid-β chaperone L-PGDS can effectively disaggregate corneal amyloids in surgically excised human cornea of TGFBI-CD patients and release trapped amyloid hallmark proteins. Since the mechanism of amyloid disassembly by ATP-independent chaperones is unknown, we reconstructed atomic models of the amyloids self-assembled from TGFBIp-derived peptides and their complex with L-PGDS using cryo-EM and NMR. We show that L-PGDS specifically recognizes structurally frustrated regions in the amyloids and releases those frustrations. The released free energy increases the chaperone’s binding affinity to amyloids, resulting in local restructuring and breakage of amyloids to protofibrils. Our mechanistic model provides insights into the alternative source of energy utilized by ATP-independent disaggregases and highlights the possibility of using these chaperones as treatment strategies for different types of amyloid-related diseases.